Disrupting Quality Standards (or Beliefs) Through Digitalization

  • The current state of digital transformation in life science
  • How to disrupt the quality standards: Digital transformation roadmap and the situation ongoing at SBL
  • Digital transformation’s Value proposition: Improve quality, productivity, and for unparalleled client experience
  • Samsung Biologics’ P4 plan and vision: We’re building the future

Sam MacHour
SVP & Chief Quality Officer
Samsung Biologics

Prior to joining Samsung Biologics in 2019, Sam spent more than 32 years supporting large MedTech, Bioscience and Biopharmaceutical companies achieve business operational excellence and gain leadership in the areas of Research & Development, Quality, Compliance, Regulatory, Operations and product commercialization. Sam’s experience covers all dosage forms, including small and large molecules, cell & gene and medical devices. In his career, Sam served in a variety of roles of increased scope and held senior and global leadership roles at Lonza, Becton Dickinson, Pfizer, J&J, Boehringer Ingelheim and GSK. Sam holds a Master’s degree from Concordia University in Physics, is a graduate of Harvard’s General Management Program and is an Alumni of and frequent contributor to the Harvard’s Kennedy School of Government and the Harvard’s Healthcare Initiative.

George Siu
Part Leader
Samsung Biologics

Samsung Biologics is a fully integrated contract service provider offering development, manufacturing, and testing services, all from a single location. We provide highly tailored solutions to clients while meeting the evolving needs of the global healthcare industry.

With proven regulatory approvals and the largest single-site capacity, Samsung Biologics is a trusted CDMO partner of choice and is uniquely able to provide seamless offerings from cell line development to final fill/finish as well as laboratory testing services at every stage for biopharmaceutical products.

Our facilities are all cGMP compliant holding 364KL total capacity with scales ranging from 1KL and 5KL to 15KL. We continue to invest and upgrade our capabilities through two 1K single-use bioreactors that provide further flexibility and efficiency in accommodating a wide range of client demands.

Samsung Biologics plans to expand its plant 4 with the largest single plant with a capacity of 256 KL.

We believe and are committed to an on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise.